SCHEMBL4674440

SCHEMBL4674440

O=C(Cc1csc(S(=O)(=O)c2ccc(F)cc2)c1)C(=O)c1nc[nH]n1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 3/20 0.34
KCNH2 Q12809 3/20 0.34
CFTR P13569 4/20 0.33
HTR2C P28335 1/20 0.32
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
EGFR P00533 1/20 0.31
ERBB2 P04626 1/20 0.31
AKR1B1 P15121 1/20 0.31
NAMPT P43490 3/20 0.30
MMP1 P03956 1/20 0.30
MMP2 P08253 1/20 0.30
MMP3 P08254 1/20 0.30
MMP9 P14780 1/20 0.30
MMP12 P39900 1/20 0.30
MMP13 P45452 1/20 0.30
MMP14 P50281 1/20 0.30
ALDH1A1 P00352 1/20 0.30
MAPT P10636 1/20 0.30
HPGD P15428 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4674871 0.90 LOXL2 (0.33) NAMPTMMP3ALDH1A1KDM4ELOXL2
SCHEMBL4679594 0.89 L3MBTL1 (0.33) KMT2AEGFRERBB2AKR1B1NAMPT
SCHEMBL4675172 0.83 CXCR3 (0.34) HTR2AKCNH2CFTRMEN1KMT2A
SCHEMBL4674792 0.82 LOX (0.33) HTR2AKCNH2CFTRHTR2CMEN1
SCHEMBL4677764 0.81 LOX (0.39) HTR2AKCNH2CFTRHTR2CSMN1; SMN2
SCHEMBL4678517 0.81 ABL1 (0.33) MEN1KMT2AALDH1A1MAPTHPGD
SCHEMBL4671870 0.80 LMNA (0.34) HTR2AKCNH2HTR2CMEN1KMT2A
SCHEMBL4671208 0.79 HTR2A (0.32) HTR2AKCNH2HTR2CEGFRERBB2
SCHEMBL4677358 0.79 KMT2A (0.39) HTR2AKCNH2HTR2CMEN1KMT2A
SCHEMBL4672159 0.79 HTR2A (0.37) HTR2AKCNH2MEN1KMT2AAKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1142872-B1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO (JP) 2008-10-15 EP disclosed
US-7098201-B2 Heteroaromatic derivatives having an inhibitory activity against HIV integrase SHIONOGI & CO., LTD. (JP) 2006-08-29 US disclosed
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase FUJISHITA TOSHIO (JP) 2004-01-01 US disclosed
US-6620841-B1 Furan or benzofuran derivatives substituted with triazole; acquired immunodeficiency syndrome (AIDS) SHIONOGI & CO., LTD. (JP) 2003-09-16 US disclosed
EP-1142872-A1 AROMATIC HETEROCYCLE COMPOUNDS HAVING HIV INTEGRASE INHIBITING ACTIVITIES SHIONOGI & CO., LTD. (JP) 2001-10-10 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040002485-A1 Heteroaromatic derivatives having an inhibitory activity against HIV integrase RCOR1, BCOR, CYP8B1 HTR2A 441/4885KCNH2 3174/4885CFTR 3324/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.